Soulpower Acquisition Corp. SOUL

Financials SIC 6770 - Blank Checks NAICS Finance and Insurance › Funds, Trusts, and Other Financial Vehicles › Other Investment Pools and Funds › Other Financial Vehicles derived NYSE

otherwise stated in this annual report or the context otherwise requires, references to:

window" are to (i) the period ending on the date that is 24 months from the closing

of our initial public offering, of such earlier liquidation date as our board of directors

may approve, in which we must complete an initial business combination or (ii) such other

Last close 10.51 2026-10-23

Market cap $269.3M 2025-12-31 share count

52-week range 10.11 - 10.83

Valuation FY2025 figures against the last close

P/S—

P/E—

P/FCF—

EV/EBITDA—

Dividend yield—

Diluted EPS—

Annual financial statements

Income statement

Fiscal year	FY2025	FY2024
SG&A	$1.7M	—
Total operating expenses	$1.7M	—
Interest expense	$100.0K	—
Net income	$6.0M	—

Balance sheet

Fiscal year	FY2025	FY2024
Total current assets	$1.5M	$100.5K
Total assets	$259.1M	$100.5K
Accounts payable	$695.9K	$43.1K
Total current liabilities	$1.7M	$166.4K
Total liabilities	$12.3M	$166.4K
Retained earnings	-$10.8M	-$90.8K
Total equity	-$10.8M	-$65.8K

Cash flow

Fiscal year	FY2025	FY2024
Operating cash flow	-$2.3M	—
Investing cash flow	-$250.0M	—
Financing cash flow	$252.5M	—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013246.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)

Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity

Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks

Revenue
Gross profit
Net income

Fiscal year	FY2024	FY2025
Revenue	—	—
Gross profit	—	—
Net income	—	$6.0M

Recent filings and events

2026-09-03 Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
2026-07-30 Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
2026-06-01 Material agreement signed Item 1.01
2026-06-01 New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
2026-04-06 Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
2026-03-31 Material agreement signed Item 1.01
2026-03-31 Regulation FD disclosure Item 7.01
2026-03-27 Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
2026-03-26 Officer or director change Item 5.02
2026-02-25 Material agreement signed Item 1.01
2026-02-25 New debt or obligation Item 2.03
2025-12-30 Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 6770

Ticker	Company	Market cap	P/E	Revenue growth
DMII	Drugs Made In America Acquisition II Corp.	$649.1M	—	—
IACO	Idea Acquisition Corp.	$437.9M	—	—
KRAQ	KRAKacquisition Corp	$430.8M	—	—
TACO	Berto Acquisition Corp.	$393.2M	36.1x	—
ALDF	Aldel Financial II Inc.	$328.0M	—	—
ATII	Archimedes Tech SPAC Partners II Co.	$290.3M	—	—
FGII	FG Imperii Acquisition Corp.	$290.3M	—	—
DMAA	Drugs Made In America Acquisition Corp.	$264.0M	—	—